Follow
Sumit Bhatnagar
Sumit Bhatnagar
Verified email at abbvie.com
Title
Cited by
Cited by
Year
A 45-amino-acid scaffold mined from the PDB for high-affinity ligand engineering
MA Kruziki, S Bhatnagar, DR Woldring, VT Duong, BJ Hackel
Chemistry & biology 22 (7), 946-956, 2015
692015
Quantitative systems pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm
V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ...
Clinical Pharmacology & Therapeutics 109 (3), 605-618, 2021
532021
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
E Khera, C Cilliers, S Bhatnagar, GM Thurber
Molecular Systems Design & Engineering 3 (1), 73-88, 2018
472018
Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design
L Zhang, S Bhatnagar, E Deschenes, GM Thurber
Scientific reports 6 (1), 25424, 2016
382016
Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors
S Bhatnagar, E Deschenes, J Liao, C Cilliers, GM Thurber
Journal of pharmaceutical sciences 103 (10), 3276-3286, 2014
302014
Oral and subcutaneous administration of a near-infrared fluorescent molecular imaging agent detects inflammation in a mouse model of rheumatoid arthritis
S Bhatnagar, E Khera, J Liao, V Eniola, Y Hu, DE Smith, GM Thurber
Scientific reports 9 (1), 4661, 2019
272019
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach
S Bhatnagar, D Mukherjee, AH Salem, D Miles, RM Menon, JP Gibbs
Cancer Chemotherapy and Pharmacology 87, 465-474, 2021
242021
Oral administration and detection of a near-infrared molecular imaging agent in an orthotopic mouse model for breast cancer screening
S Bhatnagar, KD Verma, Y Hu, E Khera, A Priluck, DE Smith, GM Thurber
Molecular pharmaceutics 15 (5), 1746-1754, 2018
232018
Fractal impeller for stirred tank reactors
AA Kulkarni, N Jha, A Singh, S Bhatnagar, BD Kulkarni
Industrial & engineering chemistry research 50 (12), 7667-7676, 2011
212011
Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
J Weddell, MS Chiney, S Bhatnagar, JP Gibbs, M Shebley
Clinical and translational science 14 (1), 395-404, 2021
112021
Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease
AA Suleiman, A Goebel, S Bhatnagar, R D'Cunha, W Liu, Y Pang
Clinical Pharmacology & Therapeutics 113 (4), 839-850, 2023
82023
Upadacitinib: Mechanism of action, clinical, and translational science
MEF Mohamed, S Bhatnagar, JM Parmentier, P Nakasato, P Wung
Clinical and Translational Science 17 (1), e13688, 2024
52024
Maribavir: Mechanism of action, clinical, and translational science
K Sun, M Fournier, AK Sundberg, IH Song
Clinical and Translational Science 17 (1), e13696, 2024
32024
Population pharmacokinetics and exposure‐response analyses for efficacy and safety of apadacitinib in patients with axial Spondyloarthritis
S Bhatnagar, D Eckert, S Stodtmann, IH Song, P Wung, W Liu, ...
Clinical and Translational Science 17 (2), e13733, 2024
2024
POS1137 PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS OF UPADACITINIB OR ELSUBRUTINIB ALONE OR IN COMBINATION (ABBV-599) IN SYSTEMIC LUPUS ERYTHEMATOUS
S Bhatnagar, L Siovitz, A Friedman, W Liu, ME Mohamed
Annals of the Rheumatic Diseases 82 (Suppl 1), 896-897, 2023
2023
Tu1733 UPADACITINIB PHARMACOKINETIC AND EXPOSURE-RESPONSE RELATIONSHIPS IN SUBJECTS WITH CROHN'S DISEASE-ANALYSES OF PHASE 3 STUDIES
S Bhatnagar, L Schlacter, D Eckert, S Stodtmann, W Liu, AP Lacerda, ...
Gastroenterology 164 (6), S-1100-S-1101, 2023
2023
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis-Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
S Bhatnagar, D Eckert, S Stodtmann, IH Song, P Wung, W Liu, ...
ARTHRITIS & RHEUMATOLOGY 74, 850-851, 2022
2022
Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK …
H Kalluri, S Bhatnagar, L Rueter, C Zadikoff, O Graff, P Noertersheuser, ...
MOVEMENT DISORDERS 36, S179-S179, 2021
2021
Protein scaffolds and methods of use
BJ Hackel, MA Kruziki, S Bhatnagar, H Zhou
US Patent 10,287,572, 2019
2019
MECHANISTIC MODELING TO UNDERSTAND INTRA-TUMOR SPATIAL DISTRIBUTION OF ANTIBODY DRUG CONJUGATES: INSIGHTS INTO DOSING STRATEGY IN ONCOLOGY.
M Chiney, S Bhatnagar, J Weddell, JP Gibbs, M Shebley
CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S27-S28, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–20